Work

Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non‐Small Cell Lung Cancer With ATM Mutation: A Case Report

Year: 2025

Type: article

Abstract: BACKGROUND: Ataxia telangiectasia mutated (ATM) mutations represent the most common homologous recombination deficiency (HRD) mutation in non-small cell lung cancer (NSCLC). However, their therapeutic role in NSCLC has not been established. CASE: Here, we present a case of a 91-year-old male with metastatic NSCLC who progressed on multiple lines of treatment. Next-generation sequencing revealed ATM mutations, leading to the initiation of olaparib, which successfully achieved remission over a two-year period. CONCLUSION: This case underscores the promising role of olaparib in treating NSCLC with HRD, particularly ATM mutations, highlighting the importance of molecular testing and targeted therapies.

Source: Cancer Reports

DOI: 10.1002/cnr2.70276

Authors: Zhiting Tang, Ran Bi, Mutasim Idriss, Qian Wang, Qi Wang, Makiko Ban‐Hoefen